Gruessner R W, Nakhleh R, Tzardis P, Platt J L, Schechner R, Gruessner A, Tomadze G, Matas A, Najarian J S, Sutherland D E
Department of Surgery, University of Minnesota, Minneapolis 55455.
Transplantation. 1993 Nov;56(5):1053-62. doi: 10.1097/00007890-199311000-00001.
Clinically, the incidence of reversible renal allograft rejection episodes appears to be higher in recipients of simultaneous pancreas/kidney (SPK) than of kidney transplantation alone (KTA); conversely, the rate of irreversible pancreas allograft rejection appears to be higher in pancreas transplant alone (PTA) than SPK recipients. Clinical/histological correlation of graft rejection in these three groups has not been precise. Therefore, we studied the incidence and histological severity of the rejection process in a large animal (pig) model of SPK (n = 36), PTA (n = 31), and KTA (n = 36) allotransplantation. SPK and PTA recipients were made diabetic pretransplant by streptozotocin (150 mg/kg). Pancreas graft exocrine secretions were bladder-drained via a duodenocystostomy for urine amylase (UA) monitoring; endocrine function was monitored by plasma glucose (PG) levels. SPK and KTA recipients underwent native nephrectomy, and renal allograft function was monitored by serum creatinine (CR). Cyclosporine, azathioprine, and prednisone were given in tapering doses from the time of transplantation. Grafts were biopsied weekly to grade histologic severity of interstitial and vascular rejection on light microscopy (LM) and for intensity of T cell infiltration on immunofluorescence. Pancreas graft exocrine function (UA above pretransplant baseline), present in 62% of PTA and 68% of SPK recipients at one week, persisted in only 7% of PTA vs. 64% of SPK pigs at 2 weeks (P = 0.0004). Likewise, pancreas graft endocrine function (PG < 200 mg/dl off insulin) was sustained longer in SPK than PTA recipients (100% vs. 84% at 1 and 91% vs. 27% at 2 weeks; P = 0.0006). However, renal allograft functional survival (serum creatinine < 3.0 mg/dl) was not significantly different (P = 0.471) between SPK and KTA recipients (36% vs. 30% at 1 and 23% vs. 13% at 2 weeks). Graft functional parameters partially correlated with biopsy observations. Pancreas allograft biopsies showed a significantly (P = 0.03 at 1 and P = 0.05 at 2 weeks) lower incidence of moderate/severe interstitial rejection in SPK than PTA recipients (67% vs. 95% at 1 and 57% vs. 92% at 2 weeks); rejection was absent in 8% of SPK and in no PTA biopsies at 1 week. Vascular rejection was moderate/severe in significantly fewer (P = 0.0013 at 1 and P = 0.023 at 2 weeks) SPK than PTA pancreas grafts (13% vs. 37% at 1 and 14% vs. 38% at 2 weeks).(ABSTRACT TRUNCATED AT 400 WORDS)
临床上,胰肾联合移植(SPK)受者中可逆性肾移植排斥反应的发生率似乎高于单纯肾移植(KTA)受者;相反,单纯胰腺移植(PTA)受者中不可逆胰腺移植排斥反应的发生率似乎高于SPK受者。这三组移植排斥反应的临床/组织学相关性并不确切。因此,我们在一个大型动物(猪)模型中研究了SPK(n = 36)、PTA(n = 31)和KTA(n = 36)同种异体移植排斥反应的发生率和组织学严重程度。SPK和PTA受者在移植前通过链脲佐菌素(150 mg/kg)诱导糖尿病。胰腺移植的外分泌通过十二指肠膀胱造口术引流至膀胱,用于监测尿淀粉酶(UA);内分泌功能通过血糖(PG)水平监测。SPK和KTA受者接受了自体肾切除术,肾移植功能通过血清肌酐(CR)监测。从移植时起,给予环孢素、硫唑嘌呤和泼尼松逐渐减量的剂量。每周对移植物进行活检,以在光学显微镜(LM)下对间质和血管排斥反应的组织学严重程度进行分级,并通过免疫荧光对T细胞浸润强度进行分级。胰腺移植外分泌功能(UA高于移植前基线)在1周时在62%的PTA受者和68%的SPK受者中存在,但在2周时仅在7%的PTA猪中持续存在,而在64%的SPK猪中持续存在(P = 0.0004)。同样,胰腺移植内分泌功能(停用胰岛素后PG < 200 mg/dl)在SPK受者中维持的时间比PTA受者更长(1周时为100%对84%,2周时为91%对27%;P = 0.0006)。然而,SPK和KTA受者之间肾移植功能存活(血清肌酐 < 3.0 mg/dl)没有显著差异(P = 0.471)(1周时为36%对30%,2周时为23%对13%)。移植物功能参数与活检观察结果部分相关。胰腺移植活检显示,SPK受者中中度/重度间质排斥反应的发生率显著低于PTA受者(1周时P = 0.03,2周时P = 0.05)(1周时为67%对95%,2周时为57%对92%);1周时8%的SPK活检标本无排斥反应,PTA活检标本均有排斥反应。SPK胰腺移植中血管排斥反应为中度/重度的明显少于PTA(1周时P = 0.0013,2周时P = 0.023)(1周时为13%对37%,2周时为14%对38%)。(摘要截断于400字)